Your browser is no longer supported. Please, upgrade your browser.
PFNX Pfenex Inc. weekly Stock Chart
Pfenex Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own0.30% Shs Outstand33.15M Perf Week14.43%
Market Cap252.61M Forward P/E16.42 EPS next Y0.48 Insider Trans- Shs Float31.88M Perf Month34.65%
Income-5.40M PEG- EPS next Q-0.28 Inst Own89.70% Short Float2.71% Perf Quarter-31.80%
Sales40.60M P/S6.22 EPS this Y102.30% Inst Trans10.39% Short Ratio2.49 Perf Half Y-25.52%
Book/sh2.51 P/B3.13 EPS next Y181.60% ROA-7.00% Target Price- Perf Year11.35%
Cash/sh2.04 P/C3.85 EPS next 5Y14.60% ROE-8.30% 52W Range5.26 - 14.00 Perf YTD-28.51%
Dividend- P/FCF- EPS past 5Y15.60% ROI1.10% 52W High-43.93% Beta0.90
Dividend %- Quick Ratio10.40 Sales past 5Y36.40% Gross Margin89.90% 52W Low49.24% ATR0.52
Employees85 Current Ratio10.40 Sales Q/Q-91.10% Oper. Margin-14.00% RSI (14)58.35 Volatility9.73% 7.53%
OptionableYes Debt/Eq0.00 EPS Q/Q-59.10% Profit Margin-13.40% Rel Volume1.05 Prev Close7.32
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume347.29K Price7.85
Recom1.60 SMA2014.88% SMA508.70% SMA200-16.15% Volume366,176 Change7.24%
Jun-01-20Resumed Oppenheimer Outperform $9 → $10
Apr-23-20Initiated Oppenheimer Outperform $9
Feb-14-20Initiated SunTrust Buy $18
Oct-25-19Initiated Cantor Fitzgerald Overweight $20
Aug-09-16Reiterated Mizuho Buy $22 → $18
May-24-16Reiterated Barclays Overweight $28 → $14
May-18-15Initiated Barclays Overweight $28
Feb-17-15Reiterated Mizuho Buy $12 → $16
Jun-03-20 04:53PM  
May-27-20 12:23PM  
May-26-20 12:55PM  
May-25-20 03:50PM  
May-18-20 07:21AM  
May-07-20 04:05PM  
May-05-20 06:15PM  
Apr-24-20 04:05PM  
Apr-17-20 10:00AM  
Apr-16-20 01:18PM  
Apr-14-20 05:04PM  
Apr-09-20 06:30PM  
Mar-16-20 07:47AM  
Mar-11-20 04:05PM  
Feb-26-20 05:03PM  
Jan-31-20 10:42AM  
Jan-15-20 12:15AM  
Jan-08-20 08:00AM  
Dec-19-19 10:21PM  
Dec-18-19 08:00AM  
Nov-20-19 04:10PM  
Nov-19-19 04:10PM  
Nov-13-19 04:40PM  
Nov-07-19 07:45PM  
Nov-06-19 04:10PM  
Oct-31-19 10:34AM  
Oct-24-19 04:30PM  
Oct-14-19 03:05PM  
Oct-11-19 10:45AM  
Oct-07-19 05:00AM  
Oct-03-19 03:49PM  
Sep-16-19 04:05PM  
Sep-10-19 04:05PM  
Sep-05-19 04:05PM  
Sep-04-19 04:05PM  
Aug-17-19 06:24PM  
Aug-08-19 07:30PM  
Aug-01-19 10:33AM  
Jul-25-19 04:10PM  
Jul-19-19 12:42PM  
Jun-25-19 08:59PM  
Jun-20-19 07:52AM  
Jun-18-19 05:45PM  
Jun-05-19 04:05PM  
May-30-19 08:01AM  
May-21-19 08:06AM  
May-09-19 07:35PM  
May-02-19 10:33AM  
Apr-25-19 04:05PM  
Apr-23-19 08:05AM  
Apr-11-19 08:05AM  
Mar-27-19 04:05PM  
Mar-26-19 04:05PM  
Mar-18-19 04:05PM  
Mar-15-19 08:29AM  
Mar-13-19 11:40PM  
Mar-11-19 05:30PM  
Mar-06-19 04:05PM  
Mar-04-19 08:05AM  
Feb-28-19 08:05AM  
Feb-27-19 04:05PM  
Feb-25-19 04:05PM  
Feb-19-19 08:05AM  
Dec-10-18 08:00AM  
Nov-26-18 08:20AM  
Nov-20-18 07:32AM  
Nov-07-18 04:05PM  
Oct-25-18 04:05PM  
Oct-01-18 04:05PM  
Sep-21-18 04:29PM  
Sep-11-18 08:00AM  
Sep-04-18 08:00AM  
Aug-23-18 09:50PM  
Aug-16-18 04:05PM  
Aug-08-18 04:05PM  
Jul-25-18 04:05PM  
Jul-12-18 08:00AM  
Jun-22-18 05:00PM  
Jun-14-18 04:15PM  
Jun-11-18 04:05PM  
May-29-18 09:10AM  
May-23-18 09:10AM  
May-22-18 04:23PM  
May-18-18 01:52PM  
May-14-18 04:02PM  
May-10-18 04:02PM  
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.